Unity Biotechnology, Inc.

NasdaqGS:UBX Stok Raporu

Piyasa değeri: US$22.1m

Unity Biotechnology Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Unity Biotechnology has a total shareholder equity of $19.8M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $53.5M and $33.8M respectively.

Anahtar bilgiler

0%

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranın/a
NakitUS$33.98m
EşitlikUS$19.75m
Toplam yükümlülüklerUS$33.77m
Toplam varlıklarUS$53.52m

Son finansal sağlık güncellemeleri

Will Unity Biotechnology (NASDAQ:UBX) Spend Its Cash Wisely?

Jul 12
Will Unity Biotechnology (NASDAQ:UBX) Spend Its Cash Wisely?

Here's Why We're A Bit Worried About Unity Biotechnology's (NASDAQ:UBX) Cash Burn Situation

Mar 05
Here's Why We're A Bit Worried About Unity Biotechnology's (NASDAQ:UBX) Cash Burn Situation

Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky

Nov 18
Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky

Recent updates

Will Unity Biotechnology (NASDAQ:UBX) Spend Its Cash Wisely?

Jul 12
Will Unity Biotechnology (NASDAQ:UBX) Spend Its Cash Wisely?

Here's Why We're A Bit Worried About Unity Biotechnology's (NASDAQ:UBX) Cash Burn Situation

Mar 05
Here's Why We're A Bit Worried About Unity Biotechnology's (NASDAQ:UBX) Cash Burn Situation

Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky

Nov 18
Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky

UNITY Biotechnology falls 7% on reverse stock split

Oct 19

Unity Biotechnology cuts stock sales agreement in half to $25M

Aug 19

Unity Biotechnology GAAP EPS of -$0.19 beats by $0.10, revenue of $0.24M

Aug 12

A Look At Unity's UBX1325 Phase 1 Results

Jul 26

Trade Alert: The Co-Founder Of Unity Biotechnology, Inc. (NASDAQ:UBX), Nathaniel David, Has Sold Some Shares Recently

Dec 22
Trade Alert: The Co-Founder Of Unity Biotechnology, Inc. (NASDAQ:UBX), Nathaniel David, Has Sold Some Shares Recently

A Look Inside Unity Bio's Transition To An Ophthalmology Company

Nov 27

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: UBX's short term assets ($35.8M) exceed its short term liabilities ($8.8M).

Uzun Vadeli Yükümlülükler: UBX's short term assets ($35.8M) exceed its long term liabilities ($25.0M).


Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: UBX is debt free.

Borcun Azaltılması: UBX had no debt 5 years ago.


Bilanço


Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: UBX has sufficient cash runway for more than a year based on its current free cash flow.

Tahmini Nakit Akışı: UBX has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 10.8% each year.


Sağlıklı şirketleri keşfedin